Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 6/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.38 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.31 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.30 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL735106 | 0.88 | SIGMAR1 (0.39) | OPRM1OPRL1SIGMAR1KCNJ1ROCK2 | |
| SCHEMBL735805 | 0.87 | SIGMAR1 (0.36) | OPRM1OPRL1SIGMAR1 | |
| SCHEMBL736045 | 0.85 | CHRNB2 (0.44) | OPRM1OPRL1SIGMAR1KCNJ1 | |
| SCHEMBL736649 | 0.82 | OPRM1 (0.42) | OPRM1OPRL1SIGMAR1 | |
| SCHEMBL736328 | 0.81 | SIGMAR1 (0.40) | OPRM1OPRL1SIGMAR1 | |
| SCHEMBL735671 | 0.80 | CHRNB2 (0.46) | OPRM1SIGMAR1 | |
| SCHEMBL737418 | 0.80 | SIGMAR1 (0.44) | OPRM1SIGMAR1MAPK1 | |
| SCHEMBL736460 | 0.79 | TRPV4 (0.39) | OPRM1OPRL1SIGMAR1KCNJ1ROCK2 | |
| SCHEMBL735954 | 0.78 | SIGMAR1 (0.40) | OPRM1OPRL1SIGMAR1ROCK2 | |
| SCHEMBL736974 | 0.78 | SIGMAR1 (0.38) | OPRM1OPRL1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138206-B2 | Piperidine derivative | MSD. K.K. (JP) | 2012-03-20 | — | — | US | disclosed |
| US-20090137576-A1 | Novel Piperidine Derivative | MSD K.K. (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-1892241-A1 | NOVEL PIPERIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-02-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137576-A1 | Novel Piperidine Derivative | HRH4, HRH3, HRH1 | OPRM1 15/4885OPRL1 33/4885SIGMAR1 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.